Advertisement
Advertisement
DERM
Journey Medical Corporation Common Stock
5.07
USDSponsored
+0.07
+1.40%
May 08, 16:00 UTC -4
Closed
Pre-Market
5.07
0.00
0.00%
DERM Earnings Reports
Positive Surprise Ratio
DERM beat 6 of 17 last estimates.
35%
Next Report
In 2 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.27M
/-$0.07
Implied change from Q4 25 (Revenue/ EPS)
+1.17%
/+75.00%
Implied change from Q1 25 (Revenue/ EPS)
+23.80%
/-61.11%
Journey Medical Corporation Common Stock earnings per share and revenue
On Mar 25, 2026, DERM reported earnings of -0.04 USD per share (EPS) for Q4 25, beating the estimate of -0.05 USD, resulting in a 21.64% surprise. Revenue reached 16.08 million, compared to an expected 19.24 million, with a -16.43% difference. The market reacted with a -30.01% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.07 USD, with revenue projected to reach 16.27 million USD, implying an increase of 75.00% EPS, and increase of 1.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Journey Medical Corporation Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Journey Medical Corporation Common Stock reported EPS of -$0.04, beating estimates by 21.64%, and revenue of $16.08M, -16.43% below expectations.
How did the market react to Journey Medical Corporation Common Stock's Q4 2025 earnings?
The stock price moved down -30.01%, changed from $6.83 before the earnings release to $4.78 the day after.
When is Journey Medical Corporation Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Journey Medical Corporation Common Stock's next earnings report?
Based on --
analysts, Journey Medical Corporation Common Stock is expected to report EPS of -$0.07 and revenue of $16.27M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement